Blueprint Medicines announces new data from ongoing Phase I clinical trial of BLU-554 in patients with advanced hepatocellular carcinoma
TRACON Pharmaceuticals announces completion of enrollment in randomized phase IIb TRAXAR study of TRC105 and Inlyta in renal cell carcinoma
Kura Oncology announces positive Phase II study for tipifarnib in HRAS mutant head and neck cancer
Blueprint Medicines to present updated data from ongoing Phase I clinical trial of BLU-554 in patients with advanced hepatocellular carcinoma at ESMO 2017 congress and 11th ILCA annual conference
TRACON Pharmaceuticals announces positive results from National Cancer Institute Phase III trial of TRC105 and Nexavar in hepatocellular cancer published in Clinical Cancer Research
Jounce Therapeutics names Hugh Cole as chief business officer and head of corporate development
Kura Oncology announces pricing of public offering of common stock
Jounce Therapeutics reports second quarter 2017 financial results
Kura Oncology announces commencement of public offering of common stock
TRACON Pharmaceuticals reports second quarter financial results and provides corporate update
Kura Oncology reports second quarter 2017 financial results and provides update on tipifarnib Phase 2 study
Blueprint Medicines to present at upcoming investor conferences in August
Blueprint Medicines reports second quarter 2017 financial results
TRACON to report second quarter company highlights and financial results on August 8 2017
Kura Oncology to report second quarter 2017 financial results
Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion
Santen and TRACON announce initiation of a phase IIa study of DE-122 for the treatment of wet age-related macular degeneration
Kura Oncology announces issuance of U.S. patent for lead product candidate Tipifarnib in head and neck cancer
Kura Oncology establishes collaboration with Foundation Medicine to support tipifarnib development in HRAS mutant head and neck cancer
Neon Therapeutics and CRISPR Therapeutics enter research collaboration
17th Annual Biotech in Europe ForumBasel
Family Office ForumZürich
59th ASH Annual MeetingAtlanta, USA
ESMO 2017 CongressMarid Spain
Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy ConferenceMainz/Frankfurt, Germany
ASCO Annual MeetingChicago
3rd Annual Immuno-Oncology: BD&L and Investment ForumChicago
Boston CEO ConferenceBoston
Keep me updated about investment opportunities in the area of oncology and life sciences.
May 2017February 2017September 2016May 2016February 2016
Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time. A link to your subscription profile can be found in every newsletter email.
Newsletters * Nextech Invest News Preview
Salutation * Ms./Mrs. Mr. Company
Company
First name *
Surname *
Address
ZIP / City
Email *
* Compulsory fields
Your eMail have been successfully registered.
